The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway

doi:10.13459/j.cnki.cjap.2016.03.003

CJAP ›› 2016, Vol. 32 ›› Issue (3): 202-206.doi: 10.13459/j.cnki.cjap.2016.03.003

Previous Articles Next Articles

The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway

DU Rui-xue¹, YE Ping¹, YAN Guang-tao², DENG Zi-hui², LIANG Wen-tao³, GUO Zi-kuan⁵, ZHANG Hong-hong⁴, GEN Miao⁴

1. Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing 100853;
2. Institue of Basic Medical Sciences, Chinese PLA General Hospital, Beijing 100853;
3. Institute of Surgery, Chinese PLA General Hospital, Beijing 100853;
4. Institute of Geriatrics, Chinese PLA General Hospital, Beijing 100853;
5. Radiology and Immunology Institute, Academy of Military Medical Sciences, Beijing 100850, China

Received:2016-01-22 Revised:2016-03-07 Online:2016-05-28 Published:2018-06-12
Supported by:
国家自然科学基金项目（81270941）

Abstract

Abstract: Objective:To investigate the effect of rosuvastatin therapy on C-C chemokine receptor(CCR2)expression in mononuclear cells in patients with carotid atherosclerosis and explore the possible upstream mechanism. Methods:Twenty patients without previous statin treatment were enrolled. Rosuvastatin were given 5 to 20 mg/day for 3 months. At baseline and 12 weeks, lipid profile and plasma monocyte chemotactic protein-1 (MCP-1) levels were examined. The mRNA and protein expressions of CCR2 in the mononuclear cells were measured with RT-PCR and flow cytometry, respectively. The mRNA and protein expression of peroxidase proliferator-activated receptor(PPAR β) were detected with RT-PCR and Western blot, respectively. Results:After 3-months rosuvastatin treatment, the patients' low-density lipoprotein cholesterol (LDL-C) levels decreased significantly (P<0.01). Compared with baseline, the mRNA and protein expressions of CCR2 in the mononuclear cells showed significantly decrease, as well as plasma MCP-1 levels (P<0.05). Both mRNA and protein expressions of PPAR β in the mononuclear cells increased (P<0.05). Conclusion:Rosuvastatin may attenuate MCP-1/CCR2 through PPARβ upstream pathway.

Key words: rosuvastatin, atherosclerosis, CCR2, PPAR β

DU Rui-xue, YE Ping, YAN Guang-tao, DENG Zi-hui, LIANG Wen-tao, GUO Zi-kuan, ZHANG Hong-hong, GEN Miao. The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway[J]. CJAP, 2016, 32(3): 202-206.

References

[1] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins[J]. Lancet, 2005, 366(9493):1267-1278.
[2] 赵佳慧, 程庆砾, 叶平. 阿托伐他汀治疗对肾脏衰老的影响[J]. 中国应用生理学杂志, 2011, 27(1):98-101.
[3] 韩磊, 叶平, 李鸣皋. PPARα信号通路在阿托伐他汀抑制衰老心肌MMP-9表达中的作用[J]. 中国应用生理学杂志, 2013, 29(5):469-472.
[4] Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy:an analysis from the JUPITER trial[J]. Lancet, 2010, 376(9738):333-339.
[5] Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro[J]. Eur J Harmacol, 2000, 410(1):83-92.
[6] Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-γand attenuates the inflammatory response in human monocytes[J]. Inflamm Res, 2002, 51(2):58-62.
[7] Olzinski AR, Turner GH, Bernard RE, et al. Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/-mouse:magnetic resonance imaging assessment[J]. Arterioscler Thromb Vasc Biol, 2010, 30(2):253-259.
[8] Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets[J]. Immunobiol, 2006, 211(6-8):609-618.
[9] Izikson L, Klein RS, Charo IF, et al. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2[J]. J Exp Med, 2000, 192(7):1075-1080.
[10] Brodmerkel CM, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodentactive CCR2 antagonist, INCB3344[J]. J Immunol, 2005, 175(8):5370-5378.
[11] Han KH, Ryu J, Hong KH, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo[J]. Circulation, 2005, 111(11):1439-1447.
[12] Yuichi M, Daisuke O, Jun W, et al. Activation of peroxisome proliferator-activated receptord inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice[J]. Diabetes, 2011, 60(3):960-968.
[13] Fan Y, Wang Y, Tang Z, et al. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2008, 28(2):315-321.
[14] Barish GD, Atkins AR, Downes M, et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis[J]. Proc Natl Acad Sci USA, 2008, 105(11):4271-4276.
[15] Schnegg CI, Kooshki M, Hsu FC, et al. PPARδ prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-κB and inhibition of the PKCα/MEK1/2/ERK1/2/AP-1 pathway[J]. Free Radical Biol Med, 2012, 52(9):1734-1743.
[16] Liu G, Li X, Li Y, et al. PPARε agonist GW501516 inhibits pdgf-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling[J]. Biomed Res Int, 2013, 2013:903947.
[17] Lazar A, Bojic, Amy C, et al. Peroxisome proliferator-activated receptorδagonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice[J]. Arterioscler Thromb Vasc Biol, 2014, 34(1):52-60.
[18] Inoue I, Itoh F, Aoyagi S, et al. Fibrate and statin synergistically increase the transcriptional activities of PPARa/RXRa and decrease the transactivation of NF-kB[J]. Biochem Biophys Res Commun, 2002, 290(1):131-139.

The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	WANG Chen-jing, PEI Shu-yan, NAN Xiao-dong, MA Yan-qing. Effects of endothelin-1 on monocyte chemotactic protein-1 production in rat vascular smooth muscle cells and its mechanism [J]. CJAP, 2018, 34(3): 283-288.
[2]	ZHOU Chang-zuan, PAN Sun-lei, LIN Hui, MENG Li-ping, JI Zheng, CHI Ju-fang, GUO Hang-yuan. Effects of rosuvastatin in homocysteine induced mouse vascular smooth muscle cell dedifferentiation and endoplasmic reticulum stress and its mechanisms [J]. CJAP, 2018, 34(1): 43-48.
[3]	WANG Min, LIU Shan-yun, ZHANG Hong-xia, WANG Ya-hui, LIU Kai. The effects of endurance training on IL-18 and IL-10 in athero-genic ApoE^-/- mice [J]. CJAP, 2016, 32(3): 225-228.